全文获取类型
收费全文 | 5596篇 |
免费 | 362篇 |
国内免费 | 17篇 |
专业分类
耳鼻咽喉 | 58篇 |
儿科学 | 355篇 |
妇产科学 | 115篇 |
基础医学 | 748篇 |
口腔科学 | 89篇 |
临床医学 | 302篇 |
内科学 | 1059篇 |
皮肤病学 | 211篇 |
神经病学 | 392篇 |
特种医学 | 138篇 |
外科学 | 995篇 |
综合类 | 128篇 |
预防医学 | 315篇 |
眼科学 | 151篇 |
药学 | 542篇 |
中国医学 | 29篇 |
肿瘤学 | 348篇 |
出版年
2023年 | 34篇 |
2022年 | 72篇 |
2021年 | 155篇 |
2020年 | 85篇 |
2019年 | 120篇 |
2018年 | 157篇 |
2017年 | 113篇 |
2016年 | 115篇 |
2015年 | 140篇 |
2014年 | 155篇 |
2013年 | 221篇 |
2012年 | 325篇 |
2011年 | 309篇 |
2010年 | 214篇 |
2009年 | 157篇 |
2008年 | 256篇 |
2007年 | 324篇 |
2006年 | 268篇 |
2005年 | 263篇 |
2004年 | 186篇 |
2003年 | 225篇 |
2002年 | 192篇 |
2001年 | 122篇 |
2000年 | 164篇 |
1999年 | 150篇 |
1998年 | 59篇 |
1997年 | 35篇 |
1996年 | 40篇 |
1994年 | 34篇 |
1993年 | 31篇 |
1992年 | 88篇 |
1991年 | 77篇 |
1990年 | 41篇 |
1989年 | 59篇 |
1988年 | 60篇 |
1987年 | 58篇 |
1986年 | 53篇 |
1985年 | 53篇 |
1984年 | 44篇 |
1983年 | 41篇 |
1982年 | 34篇 |
1979年 | 40篇 |
1977年 | 25篇 |
1976年 | 41篇 |
1975年 | 36篇 |
1974年 | 37篇 |
1973年 | 37篇 |
1971年 | 41篇 |
1970年 | 42篇 |
1969年 | 40篇 |
排序方式: 共有5975条查询结果,搜索用时 62 毫秒
1.
Tofacitinib is an immunosuppressive and disease-modifying therapy in rheumatoid arthritis. It may result in many infections flaring up. It is important to take precautions of all kinds (cardiovascular, malignancy, infections etc.) before starting tofacitinib. In this article, we have highlighted important steps where we need to take precautions before starting tofacitinib. 相似文献
2.
Madan M. Rehani Emily R. Melick Raza M. Alvi Ruhani Doda Khera Salma Batool-Anwar Tomas G. Neilan Michael Bettmann 《European radiology》2020,30(4):1839-1846
To determine percent of patients without malignancy and ≤ 40 years of age with high cumulative radiation doses through recurrent CT exams and assess imaging appropriateness. From the cohort of patients who received cumulative effective dose (CED) of ≥ 100 mSv over a 5-year period, a sub-set was identified with non-malignant disease. The top 50 clinical indications leading to multiple CTs were determined. Clinical decision support (CDS) system scores were analyzed using a widely adopted standard of 1–3 (red) as “not usually appropriate,” 4–6 (yellow) “may or may not be appropriate,” and 7–9 (green) “usually appropriate.” Clinicians reviewed patient records to assess compliance with appropriate use criteria (AUC). 9.6% of patients in our series were with non-malignant conditions and 1.4% with age ≤ 40 years. CDS scores (rounded) were 2% red, 38% yellow, 27% green, and 33% unscored CTs. Clinical society guidelines for CT exams, wherever available, were followed in 87.5 to 100% of cases. AUCs were not available for several clinical indications as also referral guidelines for serial CT imaging. More than half of CT exams were unrelated to follow-up of a primary chronic disease. We are faced with a situation wherein patients in age ≤ 40 years require or are thought to require many CT exams over the course of a few years but the radiation risk creates concern. There is a fair number of conditions for which AUC are not available. Suggested solutions include development of CT scanners with lesser radiation dose and further development of appropriateness criteria. 相似文献
3.
4.
5.
6.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献7.
8.
9.